Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ficerafusp alfa (BCA101)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biocon

Drug class:

EGFR inhibitor, TGFβ inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

luspatercept-aamt (4)

sotatercept-csrk (0)

›

EGFR amplification	Lung Non-Small Cell Squamous Cancer	EGFR amplification	Lung Non-Small Cell Squamous Cancer	BCA101 Sensitive: C3 – Early Trials BCA101 Sensitive : C3	BCA101 Sensitive: C3 – Early Trials BCA101 Sensitive : C3
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + BCA101 Sensitive: C3 – Early Trials pembrolizumab + BCA101 Sensitive : C3	pembrolizumab + BCA101 Sensitive: C3 – Early Trials pembrolizumab + BCA101 Sensitive : C3
EGFR expression	Solid Tumor	EGFR expression	Solid Tumor	BCA101 Sensitive: D – Preclinical BCA101 Sensitive : D	BCA101 Sensitive: D – Preclinical BCA101 Sensitive : D